Autotelic Bio has successfully closed its Series B Bridge round with investments from Kiwoom Securities and others. This round is crucial for their upcoming IPO and ongoing drug development efforts.
PRIVATEJun 29, 2026
Round Type
Series B
San DiegoBiotechnologyHealth CarePharmaceutical
Investors
Vine VenturesMega FactoryKiwoom Securities
Description
Autotelic Bio closed its Series B Bridge investment round, securing support from Kiwoom Securities, a strategic investor, and major reinvestments from Vine Ventures. This funding is aimed at facilitating their initial public offering and advancing the development of ATB-101. The company has cleared critical regulatory hurdles for its Phase 1 trial in the US. Follow-up investments show strong investor confidence in Autotelic Bio's technology and growth potential.
Who to call at Autotelic Bio, and when
A new round usually means Autotelic Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Autotelic Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Autotelic Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Autotelic Bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Autotelic Bio
Location
San Diego, California, United States
About
Autotelic Bio is an RNA innovative drug developer focused on creating treatments for hypertension and diabetes. They have developed ATB-101, a combination drug that operates on a modular platform, capable of expanding into various pipelines. The company has recently received FDA approval for the Phase 1 clinical trial of ATB-101 in the US market. They are in the process of securing funding for their initial public offering while also advancing their drug development domestically.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Autotelic Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealth CarePharmaceutical